simulect- basiliximab injection, powder, for solution
novartis pharmaceuticals corporation - basiliximab (unii: 9927mt646m) (basiliximab - unii:9927mt646m) - basiliximab 10 mg in 2.5 ml - simulect® (basiliximab) is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine, usp (modified), and corticosteroids. the efficacy of simulect for the prophylaxis of acute rejection in recipients of other solid organ allografts has not been demonstrated. simulect® (basiliximab) is contraindicated in patients with known hypersensitivity to basiliximab or any other component of the formulation. see composition of simulect under description. simulect® (basiliximab) should be administered under qualified medical supervision. patients should be informed of the potential benefits of therapy and the risks associated with administration of immunosuppressive therapy. while neither the incidence of lymphoproliferative disorders nor opportunistic infections was higher in simulect-treated patients than in placebo-treated patients, patients on immunosuppressive therapy are at increased risk for dev
basilicum-injeel forte liq (4d,10d,30d,200d/1.1ml) liquid
biologische heilmittel heel gmbh - basil (ocimum basilicum) - liquid - 4d - basil (ocimum basilicum) 4d - homeopathic products
simulect 20 mg
novartis israel ltd - basiliximab - powder and solvent for solution for injection/infusion - basiliximab 20 mg/vial - basiliximab - basiliximab - prophylaxis of acute organ rejection in de novo renal transplantation in combination with cyclosporin and corticosteroid based immunosuppression
simulect basiliximab (rmc) 20mg powder for injection vial and diluent ampoule
novartis pharmaceuticals australia pty ltd - basiliximab, quantity: 20 mg - injection, powder for - excipient ingredients: sucrose; mannitol; glycine; monobasic potassium phosphate; sodium chloride; dibasic sodium phosphate - simulect is indicated for the prophylaxis of acute organ rejection in renal transplantation.
ocimum basilicum globules
dolisos canada inc. - basil (ocimum basilicum) - globules - 1x - basil (ocimum basilicum) 1x - homeopathic products
simulect basiliximab (rmc) 10mg powder for injection vial with diluent ampoule
novartis pharmaceuticals australia pty ltd - basiliximab -
simulect
novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunosuppressants - simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years).it is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
simulect
novartis new zealand ltd - basiliximab 10mg (murine/human; formulated with a 7.5% total overage); - powder for injection - 10 mg - active: basiliximab 10mg (murine/human; formulated with a 7.5% total overage) excipient: dibasic sodium phosphate glycine mannitol monobasic potassium phosphate sodium chloride sucrose water for injection - simulect is indicated for the prophylaxis of acute organ rejection in de novo renal transplantation in adult and paediatric patients. it is to be used concomitantly with cyclosporin for microemulsion- and corticosteroid-based immunosuppression or in a triple maintenance immunosuppressive regimen containing cyclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
simulect
novartis new zealand ltd - basiliximab 20mg (murine/human; formulated with a 7.5% total overage) - powder for injection - 20 mg - active: basiliximab 20mg (murine/human; formulated with a 7.5% total overage) excipient: dibasic sodium phosphate glycine mannitol monobasic potassium phosphate sodium chloride sucrose water for injection - simulect is indicated for the prophylaxis of acute organ rejection in de novo renal transplantation in adult and paediatric patients. it is to be used concomitantly with cyclosporin for microemulsion- and corticosteroid-based immunosuppression or in a triple maintenance immunosuppressive regimen containing cyclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
basil pure essential oil
heritage brands ltd - ocimum basilicum, quantity: 1 ml/ml (equivalent: methyl chavicol, qty 319 microlitre/ml; equivalent: eugenol, qty 39 microlitre/ml; equivalent: methyl eugenol, qty 0 microlitre/ml; equivalent: cineole, qty 55 microlitre/ml) - essential oil - excipient ingredients: - traditionally used in aromatherapy to maintain/support general health and wellbeing ; traditionally used in aromatherapy to anti-inflammatory/relieve inflammation ; traditionally used in aromatherapy to decrease/reduce/relieve mild joint aches and pains ; traditionally used in aromatherapy to decrease/reduce/relieve mild rheumatic aches and pains ; traditionally used in aromatherapy to decrease/reduce/relieve flatulence/carminative ; traditionally used in aromatherapy to decrease/reduce/relieve abdominal spasm ; traditionally used in aromatherapy to decrease/reduce/relieve symptoms of indigestion/dyspepsia ; traditionally used in aromatherapy to decrease/reduce/relieve muscle cramps ; traditionally used in aromatherapy to decrease/reduce/relieve muscle pain/ache/soreness ; traditionally used in aromatherapy to decrease/reduce/relieve symptoms of stress ; traditionally used in aromatherapy to decrease/reduce/relieve nervous tension/unrest ; traditionally used in aromatherapy to decrease/reduce/relieve symptoms of mild anxiety ; traditionally used in aromatherapy to maintain/support mental concentration/focus/clarity ; traditionally used in aromatherapy to decrease/reduce/relieve headache symptoms ; traditionally used in aromatherapy to decrease/reduce/relieve menstrual spasms/cramps